Sign in

AERI on NASDAQ

Aerie Pharmaceuticals

Aerie Pharmaceuticals was an American clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates were once-daily therapies for lowering intraocular pressure with mechanisms to treat patients with glaucoma or ocular hypertension. In August 2022, Swiss eye-care firm Alcon agreed to buy Aerie Pharmaceuticals for US$770 million.3 It was founded in 2005.1 It is headquartered in Durham.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Jan 1, 2005Founded1

Compare with Adaptimmune (United Kingdom), REGENXBIO Inc. or Maze Therapeutics, Inc., or pick any stock.

  • TickerAERI on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersDurham1
  • Websitewww.aeriepharma.com
  • Incorporated inDE5
  • Business address4301 Emperor Boulevard, Suite 400, Durham, Nc 277035
  • Filer categoryLarge accelerated filer5
  • Legal formCorporation4
  • LEI529900SFXHDHUO324R094
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressc/o The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 39892704

See how the biggest companies compare on our leaderboards

Aerie Pharmaceuticals was an American clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates were once-daily therapies for lowering intraocular pressure with mechanisms to treat patients with glaucoma or ocular hypertension.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-23.9%Operating margin6
-38.5%Net margin6
133.5%Revenue growth, 20216
-$102.4MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue11¢$26.8M
  • Research and development31¢$75.8M
  • Selling, general and admin57¢$137.8M
  • Income tax0¢$593.0K

Out of $194.1M in revenue.6 The company lost money this year.

Financial statements

Revenue7896$194.1M in 2021
0$50.0M$100.0M$150.0M$200.0M2016: $0$020162017: $0$020172018: $24.2M$24.2M20182019: $69.9M$69.9M2019+189%2020: $83.1M$83.1M2020+19%2021: $194.1M$194.1M2021+134%
Operating income107896-$46.4M in 2021−38% since 2015
-$300.0M-$200.0M-$100.0M02015: -$75.1M-$75.1M20152016: -$96.9M-$96.9M2016+29%2017: -$145.7M-$145.7M2017+50%2018: -$209.7M-$209.7M2018+44%2019: -$187.5M-$187.5M2019−11%2020: -$155.7M-$155.7M2020−17%2021: -$46.4M-$46.4M2021−70%
Net income107896-$74.8M in 2021+1% since 2015
-$300.0M-$200.0M-$100.0M02015: -$74.4M-$74.4M20152016: -$99.1M-$99.1M2016+33%2017: -$145.1M-$145.1M2017+46%2018: -$232.6M-$232.6M2018+60%2019: -$199.6M-$199.6M2019−14%2020: -$183.1M-$183.1M2020−8%2021: -$74.8M-$74.8M2021−59%
Fiscal year2015201620172018201920202021
Revenue$07$08$24.2M9$69.9M6$83.1M6$194.1M6
Cost of revenue$07$07$641.0K9$4.8M6$25.3M6$26.8M6
Research and development$44.5M10$52.4M7$72.1M8$86.1M9$91.4M6$74.0M6$75.8M6
Selling, general and admin$30.6M10$34.7M7$56.9M8$120.6M9$138.4M6$137.2M6$137.8M6
Operating expenses$240.5M6
Operating income-$75.1M10-$96.9M7-$145.7M8-$209.7M9-$187.5M6-$155.7M6-$46.4M6
Interest$2.5M13$2.5M13
Income before tax-$74.2M6
Income tax$139.0K10$193.0K7-$1.8M8$3.0K9-$90.0K6$5.2M6$593.0K6
Net income-$74.4M10-$99.1M7-$145.1M8-$232.6M9-$199.6M6-$183.1M6-$74.8M6
Earnings per share-$4.396-$3.996-$1.616
Earnings per share (diluted)-$4.396-$3.996-$1.616
Shares (weighted, basic)46.3M shares6
Shares (weighted, diluted)46.3M shares6

Compare Aerie Pharmaceuticals with another company

Corporate structure

Aerie Pharmaceuticals sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Aerie Pharmaceuticals

  • James E. Flynn Filed SC 13G/A on Aerie Pharmaceuticals, latest Feb 10, 2023 (2 filings since Feb 11, 2022)
  • Morgan Stanley Filed SC 13G/A on Aerie Pharmaceuticals, latest Nov 10, 2022 (2 filings since Feb 9, 2022)
  • PFM Health Sciences, LP Filed SC 13G/A on Aerie Pharmaceuticals, latest Feb 14, 2022
  • VANGUARD GROUP INC Filed SC 13G/A on Aerie Pharmaceuticals, latest Feb 9, 2022
  • BlackRock Filed SC 13G/A on Aerie Pharmaceuticals, latest Feb 3, 2022
  • Aerie Pharmaceuticals Durham, North Carolina, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Aerie Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$74.2M6 Dec 31, 2021$70.8M6 Dec 31, 2020+4.8%
Accumulated depreciation$22.7M6 Dec 31, 2021$16.6M6 Dec 31, 2020+37.2%
Property and equipment, net$51.5M6 Dec 31, 2021$54.3M6 Dec 31, 2020−5.1%
Operating-lease assets (leased space)$22.7M6 Dec 31, 2021$14.1M6 Dec 31, 2020+61.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$37.2M6 Dec 31, 2021$151.6M6 Dec 31, 2020−75.5%
Marketable securities, current$102.6M6 Dec 31, 2021$88.8M6 Dec 31, 2020+15.6%
Debt securities available for sale$102.6M6 Dec 31, 2021$88.8M6 Dec 31, 2020+15.6%
Equity securities at fair value$1.3M6 Dec 31, 2021$1.3M9 Dec 31, 20200%

Inventory

ItemLatestA year beforeChange
Inventory, total$40.4M6 Dec 31, 2021$27.1M6 Dec 31, 2020+49.3%
Raw materials$5.4M6 Dec 31, 2021$1.9M6 Dec 31, 2020+186.3%
Work in process$31.0M6 Dec 31, 2021$21.6M6 Dec 31, 2020+43.1%
Finished goods$4.1M6 Dec 31, 2021$3.5M6 Dec 31, 2020+14.6%

Leadership

Who has led Aerie Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Vicente Anido Jr.2013–2021
  2. Raj Kannan2021–2022

Chair

  1. Benjamin F. McGraw Iii.2021–2022

President

  1. Thomas A. Mitro2013–2022

Chief financial officer

  1. Richard J. Rubino2013–2021
  2. Christopher Staten2021
  3. Peter Frederick Lang2022

Chief operating officer

  1. Thomas A. Mitro2013–2022
2010201520202025
Board members and other officers (20)

Timeline

  1. Nov 21, 20228-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale39
  2. Nov 18, 20228-K Shareholder vote40
  3. Nov 7, 20228-K Other events41
  4. Nov 3, 20228-K Results of operations; Regulation FD disclosure42
  5. Sep 13, 20228-K Regulation FD disclosure43
  6. Aug 23, 20228-K Regulation FD disclosure44
  7. Aug 23, 20228-K Entered a material agreement45
  8. Aug 5, 20228-K Results of operations46
  9. Aug 1, 20228-K Regulation FD disclosure47
  10. Jun 13, 20228-K Shareholder vote48
  11. Jun 8, 20228-K Regulation FD disclosure49
  12. May 25, 20228-K Regulation FD disclosure50
  13. Dec 22, 2021New chief executive Raj Kannan becomes CEO14
  14. Oct 25, 2013New chief executive Vicente Anido Jr. becomes CEO15
  15. Oct 25, 2013Went public Listed on NASDAQ1
  16. Jan 1, 2005Founded Founded1

Calendar

When it reported results

  1. Nov 3, 2022Reported quarterly or annual results42
  2. Aug 5, 2022Reported quarterly or annual results46
  3. May 5, 2022Reported quarterly or annual results51
  4. Feb 24, 2022Reported quarterly or annual results52
  5. Nov 4, 2021Reported quarterly or annual results53

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

105 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 29 major events, 42 insider forms, 7 large holders, 22 other. The latest 20:

  1. Feb 10, 2023SC 13G/A EDGAR
  2. Dec 1, 202215-12G EDGAR
  3. Nov 21, 202225-NSE EDGAR
  4. Nov 21, 20224 FORM 4 SUBMISSION EDGAR
  5. Nov 21, 20224 FORM 4 SUBMISSION EDGAR
  6. Nov 21, 20224 FORM 4 SUBMISSION EDGAR
  7. Nov 21, 20224 FORM 4 SUBMISSION EDGAR
  8. Nov 21, 20224 FORM 4 SUBMISSION EDGAR
  9. Nov 21, 20224 FORM 4 SUBMISSION EDGAR
  10. Nov 21, 20224 FORM 4 SUBMISSION EDGAR
  11. Nov 21, 20224 FORM 4 SUBMISSION EDGAR
  12. Nov 21, 20224 FORM 4 SUBMISSION EDGAR
  13. Nov 21, 20224 FORM 4 SUBMISSION EDGAR
  14. Nov 21, 20224 FORM 4 SUBMISSION EDGAR
  15. Nov 21, 2022S-8 POS EDGAR
  16. Nov 21, 2022S-8 POS EDGAR
  17. Nov 21, 2022S-8 POS EDGAR
  18. Nov 21, 2022S-8 POS EDGAR
  19. Nov 21, 2022S-8 POS EDGAR
  20. Nov 21, 2022S-8 POS EDGAR

The 105 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Aerie Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAERIE PHARMACEUTICALS INC2
  • CIK0001337553
  • Employer ID (EIN)20-31095652
  • Filer statusLarge accelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • Business address4301 Emperor Boulevard, Suite 400, Durham, NC 277032
  • Phone(919) 237-53002
  • Shares outstanding49,417,407 as of Oct 28, 202212
  • Public float$734.9M as of Jun 30, 20216
  • On EDGAR sinceAug 26, 20052
  • Filings818 in all: 8-K (295), 4 (252), SC 13G/A (62), 3 (33), 10-Q (28), SC 13G (18), 424B5 (10), DEFA14A (10)2
    All 42 form types

    10-K (9), CORRESP (9), DEF 14A (9), SC 13D/A (9), UPLOAD (9), S-8 (8), S-8 POS (8), 5 (5), 3/A (4), D (4), SC 13D (4), 4/A (3), REGDEX (3), S-1/A (3), 8-K/A (2), CT ORDER (2), EFFECT (2), 15-12G (1), 25-NSE (1), 424B4 (1), 424B7 (1), 8-A12B (1), ARS (1), CERTNAS (1), D/A (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), PREM14A (1), S-1 (1), S-1MEF (1), S-3 (1), S-3ASR (1)

  • Latest filingsAnnual report (10-K) Feb 25, 2022
    Quarterly report (10-Q) Nov 4, 2022
    Proxy statement (DEF 14A) Apr 26, 2022
    Latest 8-K (8-K) Nov 21, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
    SEC EDGAROther events
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58